Jiajing Jia1,2,3, Ying Yang4,5,6,7, Fangchao Liu8,9,10, Minjin Zhang2,3, Qin Xu1,2,3, Tonglei Guo2,3, Long Wang2,11, Zuoqi Peng2,3, Yuan He1,2,3, Yuanyuan Wang2,3,12, Ya Zhang2,3, Hongguang Zhang2,3, Haiping Shen13, Yiping Zhang13, Donghai Yan13, Xu Ma14,15,16, Puhong Zhang17. 1. Graduate School of Peking, Union Medical College, Beijing, People's Republic of China. 2. National Research Institute for Family Planning, Da Huisi Road, 12#, Beijing, People's Republic of China. 3. National Human Genetic Resources Center, Beijing, People's Republic of China. 4. Graduate School of Peking, Union Medical College, Beijing, People's Republic of China. angela-yy65@hotmail.com. 5. National Research Institute for Family Planning, Da Huisi Road, 12#, Beijing, People's Republic of China. angela-yy65@hotmail.com. 6. National Human Genetic Resources Center, Beijing, People's Republic of China. angela-yy65@hotmail.com. 7. China DOHaD Research Center, Beijing, People's Republic of China. angela-yy65@hotmail.com. 8. Department of Epidemiology, Fuwai Hospital, Beijing, People's Republic of China. 9. National Center for Cardiovascular Disease, Beijing, People's Republic of China. 10. China Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. 11. School of Public Health, Institute of Epidemiology and Statistics, Lanzhou University, Lanzhou, People's Republic of China. 12. China DOHaD Research Center, Beijing, People's Republic of China. 13. Department of Maternal and Child Health, National Health and Family Planning Commission of the PRC, Beijing, People's Republic of China. 14. Graduate School of Peking, Union Medical College, Beijing, People's Republic of China. nfpcc_ma@163.com. 15. National Research Institute for Family Planning, Da Huisi Road, 12#, Beijing, People's Republic of China. nfpcc_ma@163.com. 16. National Human Genetic Resources Center, Beijing, People's Republic of China. nfpcc_ma@163.com. 17. Diabetes Research Program, The George Institute for Global Health At Peking University Health Science Center, Zhi Chun Road, 6#, Beijing, People's Republic of China. zpuhong@georgeinstitute.org.cn.
Abstract
BACKGROUND: Inconsistent results were found in the association between serum alanine aminotransferase (ALT) and hypertension among population-based studies. This study evaluated the association between ALT and hypertension among Chinese reproductive-age population by utilizing registration data from National Free Pre-pregnancy Checkups Project in 2016-2017. METHODS: The 21,103,790 registered participants were eligible for analysis, including women who were 20-49 years old and men who were 20-59 years old with available data for ALT and blood pressure (BP). Logistic regression was conducted to estimate odds ratio (OR) for the association between ALT and hypertension as a binary outcome. Linear regression was used to examine the association between ALT and BP as a continuous outcome. RESULTS: In total, 4.21% of the participants were hypertensive, and 11.67% had elevated ALT (> 40 U/L). Hypertension prevalence was 3.63% and 8.56% among participants with normal and elevated ALT levels. A strong linear relationship was found between serum ALT levels and the odds of hypertension after adjustment for potential confounders. The multivariable-adjusted ORs for hypertension were 1, 1.22 (1.21, 1.22), 1.67 (1.65 1.68), 1.78 (1.76, 1.80), and 1.92 (1.90, 1.94) in participants with ALT levels of ≤ 20, 20.01-40, 40.01-60, 60.01-80, and > 80 U/L, respectively. Systolic and diastolic BPs rose by 1.83 and 1.20 mmHg on average, for each 20 U/L increase in ALT (P for trend < 0.001). The association was consistent among subgroups and tended to be stronger among populations who are overweight (body mass index ≥ 24 kg/m2) (χ2 = 52,228, P < 0.001), alcohol drinking (χ2 = 100,730, P < 0.001) and cigarette smoking (χ2 = 105,347, P < 0.001). CONCLUSIONS: Our cross-sectional analysis suggested a linear association between serum ALT and hypertension or BP, which indicated that abnormal liver metabolism marked by elevated serum ALT could play a role in hypertension or elevated BP condition.
BACKGROUND: Inconsistent results were found in the association between serum alanine aminotransferase (ALT) and hypertension among population-based studies. This study evaluated the association between ALT and hypertension among Chinese reproductive-age population by utilizing registration data from National Free Pre-pregnancy Checkups Project in 2016-2017. METHODS: The 21,103,790 registered participants were eligible for analysis, including women who were 20-49 years old and men who were 20-59 years old with available data for ALT and blood pressure (BP). Logistic regression was conducted to estimate odds ratio (OR) for the association between ALT and hypertension as a binary outcome. Linear regression was used to examine the association between ALT and BP as a continuous outcome. RESULTS: In total, 4.21% of the participants were hypertensive, and 11.67% had elevated ALT (> 40 U/L). Hypertension prevalence was 3.63% and 8.56% among participants with normal and elevated ALT levels. A strong linear relationship was found between serum ALT levels and the odds of hypertension after adjustment for potential confounders. The multivariable-adjusted ORs for hypertension were 1, 1.22 (1.21, 1.22), 1.67 (1.65 1.68), 1.78 (1.76, 1.80), and 1.92 (1.90, 1.94) in participants with ALT levels of ≤ 20, 20.01-40, 40.01-60, 60.01-80, and > 80 U/L, respectively. Systolic and diastolic BPs rose by 1.83 and 1.20 mmHg on average, for each 20 U/L increase in ALT (P for trend < 0.001). The association was consistent among subgroups and tended to be stronger among populations who are overweight (body mass index ≥ 24 kg/m2) (χ2 = 52,228, P < 0.001), alcohol drinking (χ2 = 100,730, P < 0.001) and cigarette smoking (χ2 = 105,347, P < 0.001). CONCLUSIONS: Our cross-sectional analysis suggested a linear association between serum ALT and hypertension or BP, which indicated that abnormal liver metabolism marked by elevated serum ALT could play a role in hypertension or elevated BP condition.
Authors: Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright Journal: Circulation Date: 2018-10-23 Impact factor: 29.690
Authors: Lin Xu; Chao Qiang Jiang; Tai Hing Lam; Wei Sen Zhang; Feng Zhu; Ya Li Jin; G Neil Thomas; Kar Keung Cheng; C Mary Schooling Journal: Hum Mol Genet Date: 2017-01-15 Impact factor: 6.150